A study in people with cystic fibrosis (a rare hereditary lung disease) to assess the efficacy and safety of two experimental drugs: ivacaftor and VX-661 in combination with ivacaftor To evaluate the efficacy of VX-661 in combination with ivacaftor and ivacaftor monotherapy through 8 weeks of treatment in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutat...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Clinical Study to evaluate the Safety, Tolerability, and the effects of VX-970 in combination with Chemotherapy on the body in Subjects with Advanced Solid Tumors -To evaluate the safety/tolerability of intravenous VX-970 administered: Part A – as multiple ascending doses in comb with gem, and with cis/gem in subjects with advanced solid tumors Part B – as mu...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non- G551D CFTR Mutation To evaluate the safety of long-term ivacaftor treatment in subjects with cystic fibrosis (CF)

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Clinical Study to evaluate the Safety, Tolerability, and the effects of VX-970 on its own and in combination with Carboplatin on the body in Subjects with Advanced Solid Tumors PART A To determine the maximum tolerated dose (MTD) and evaluate the safety and tolerability of multiple ascending doses of VX 970 administered once weekly (Part A1) or twice weekly (Part A2) as a si...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis - To define the clinical response to placebo and two doses of VX-702 in subjects with RA using the number of 20% responses as defined by the American College of Rheumatology (ACR20) at Week 12 by appl...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to assess the efficacy and safety of a combination of two experimental drugs in people with cystic fibrosis (a rare hereditary lung disease) Estudio para evaluar la eficacia y seguridad de una combinación de dos farmacos experimentales en personas con fibrosis quística (una enfermedad pulmonar hereditaria rara) To evaluate the long-term safety and tolerability of VX-661 in combination with ivacaftor in subjects with CF, homozygous or heterozygous for the F508del-CFTR mutation who are in the Treatment Cohort....

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Roll-over study in children with Cystic Fibrosis (a rare hereditary pulmonary disease) to assess the long-term safety and pharmacodynamics of ivacaftor To evaluate the long-term safety of ivacaftor treatment

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2, Multicenter, Double Blinded, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/Ivacaftor Cotherapy in Subjects with Cystic Fibrosis, Homozygous or Heterozygous for the F508del CFTR Mutation -To evaluate the safety and tolerability of VX-661 monotherapy and VX-661/VX-770 cotherapy -To evaluate the effect of VX-661 monotherapy and VX-661/VX-770 cotherapy on CFTR function

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study in people with Cystic Fibrosis ( a rare hereditary pulmonary disease) to assess the efficacy and safety of a combination of two experimental drugs Uno studio condotto in pazienti con fibrosi cistica (una rara malattia ereditaria polmonare) per valutare l'efficacia e la sicurezza di una combinazione di due farmaci sperimentali To evaluate the efficacy of lumacaftor in combination with ivacaftor through Week 24 in subjects with Cystic Fibrosis who are homozygous for the F508del-CFTR mutation Valutazione dell'efficacia ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Who did not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response To provide access to a telaprevir-based treatment to subjects enrolled in the Peg IFN alfa-2a plus ribavirin Control Group (Group A) of Studies VX06 950-106 (Study 106), VX05-950-104 (Study 104) or VX...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune